10.7 C
London
Sunday, February 23, 2025
HomeMarketsEurope Markets

Europe Markets

spot_img

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 February 2025

At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities, which cover all aspects of the risk management...

Opfolda | European Medicines Agency (EMA)

OverviewOpfolda is a medicine used in the treatment of adults with late-onset Pompe disease (acid alpha-glucosidase deficiency), an inherited disorder in which...

Fasenra | European Medicines Agency (EMA)

OverviewFasenra is an asthma medicine used to treat adults with a particular type of asthma called eosinophilic asthma. It is used as an...

Beyfortus | European Medicines Agency (EMA)

OverviewBeyfortus is a medicine used to prevent serious lower respiratory tract (lung) disease caused by respiratory syncytial virus (RSV) in newborns and children...

Karvea | European Medicines Agency (EMA)

OverviewThis is a summary of the European public assessment report (EPAR) for Karvea. It explains how the Committee for Medicinal Products for Human...

Lyumjev (previously Liumjev) | European Medicines Agency (EMA)

OverviewLyumjev is a medicine used to control blood glucose (sugar) levels in adults and children aged 1 year and above with diabetes. It...

Dimethyl fumarate Neuraxpharm | European Medicines Agency (EMA)

OverviewDimethyl fumarate Neuraxpharm is a medicine used to treat multiple sclerosis (MS), a disease in which inflammation damages the protective insulation around nerves...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read

spot_img